Growth Hormone Therapy in Neurosecretory Dysfunction

Area of Science:

• Pediatric Endocrinology
• Genetics
• Growth Disorders

Background:

• Growth hormone neurosecretory dysfunction (GH-NSD) is a rare condition causing short stature.
• Diagnosis involves assessing nocturnal growth hormone secretion alongside normal stimulation tests.
• Recombinant human growth hormone (rhGH) is a potential treatment for GH-NSD.

Purpose of the Study:

• To evaluate the treatment response and final height in GH-NSD patients receiving rhGH.
• To analyze first- and second-year treatment outcomes.
• To assess the correlation between baseline parameters and treatment response.

Main Methods:

• Retrospective study of 18 patients diagnosed with GH-NSD.
• Assessment of baseline parameters: IGF-1, GH stimulation tests, mean GH during sleep, height SDS, MPH, and PAH.
• Analysis of treatment response (height velocity, height SDS) at year 1, year 2, and final height.

Main Results:

• rhGH therapy improved height velocity and overall height in GH-NSD patients.
• Mean baseline height SDS was -3.13; after treatment, final height SDS averaged -1.72.
• Significant improvements in height SDS were observed in the first and second years of treatment.

Conclusions:

• Patients with GH-NSD demonstrate a positive response to rhGH treatment.
• rhGH therapy aids patients in reaching their predicted genetic height potential.
• Baseline height SDS, predicted adult height SDS, and mid-parental height SDS correlate with first-year height velocity.